 |
|
The Case for Randomized Trials in Cancer Treatment
New Is Not Always Better
Alison Grann, MD;
Victor R. Grann, MD, MPH
JAMA. 2005;293:1001-1003.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Given a choice, most patients diagnosed with cancer would prefer the most recently discovered treatments, prompting them to seek out the latest innovation, even if it includes relatively untried medications that have not been thoroughly evaluated.1-2 In the mid 1950s, pioneering cancer researchers, anticipating the need for clinical trials, requested funds from the US Congress for the development of the first clinical research cooperative groups.3 A small network of institutions was formed to test new anticancer agents arising from the National Cancer Institute’s Drug Development Program. Eleven of the original groups remain and 3 are dedicated to specific areas of therapy such as the Radiation Therapy Oncology Group (RTOG), the American College of Surgeons, and the American College of Radiology Imaging Network. Nineteen hundred institutions are involved, with more than 60% of patients who participate in publicly or privately funded clinical cancer . . . [Full Text of this Article]
Author Affiliations: Department of Radiation Oncology, St Barnabas Medical Center, Livingston, NJ, and the Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, and the Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.
RELATED ARTICLE
Evaluation of New Treatments in Radiation Oncology: Are They Better Than Standard Treatments?
Heloisa P. Soares, Ambuj Kumar, Stephanie Daniels, Suzanne Swann, Alan Cantor, Iztok Hozo, Mike Clark, Fadila Serdarevic, Clement Gwede, Andy Trotti, and Benjamin Djulbegovic
JAMA. 2005;293(8):970-978.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Treatment Success in Cancer: New Cancer Treatment Successes Identified in Phase 3 Randomized Controlled Trials Conducted by the National Cancer Institute-Sponsored Cooperative Oncology Groups, 1955 to 2006
Djulbegovic et al.
Arch Intern Med 2008;168:632-642.
ABSTRACT
| FULL TEXT
Using causal models to show the effect of untestable assumptions on effect estimates in randomized controlled trials
Allard and Boivin
Clin Trials 2007;4:611-620.
ABSTRACT
Treatment Tolerance and Efficacy in Geriatric Oncology: A Systematic Review of Phase III Randomized Trials Conducted by Five National Cancer Institute-Sponsored Cooperative Groups
Kumar et al.
JCO 2007;25:1272-1276.
ABSTRACT
| FULL TEXT
|
